This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Photo Release -- Alimera Sciences Announces Key Executive Promotions

ATLANTA, Aug. 16, 2010 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced the promotions of Richard S. Eiswirth, Jr. to chief operating officer, and David R. Holland to senior vice president of sales and marketing. Mr. Eiswirth, who retains the position of chief financial officer in addition to his new role, will continue to oversee Alimera's finances and growth strategy implementation. Mr. Holland, a co-founder of Alimera who has served as vice president of marketing since 2003, will manage corporate communications and product sales and marketing, including managed markets, professional and consumer outreach, advertising and public relations.
David R. Holland
David R. Holland
Richard S. Eiswirth, Jr.
Richard S. Eiswirth, Jr.

Photos accompanying this release are available at

At the end of the year, Alimera expects to receive an action letter from the FDA in response to its New Drug Application for its intravitreal insert, Iluvien®, for the treatment of diabetic macular edema. In their expanded roles, Messrs. Eiswirth and Holland will guide the U.S. commercialization of Iluvien.

"Alimera Sciences is on the brink of providing a much needed long-term treatment for diabetic macular edema, and it is essential to appropriately align our resources and delineate responsibilities for this endeavor," said Dan Myers, Alimera's president and CEO. "I am pleased to announce the promotions of Rick and Dave, whose hard work and dedication have been integral to the growth and success of our company. I am confident they will make significant contributions as we plan for and execute the Iluvien launch."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ALIM $2.10 -0.47%
AAPL $110.78 0.36%
FB $94.01 2.11%
GOOG $641.47 2.32%
TSLA $246.15 -0.57%


Chart of I:DJI
DOW 16,776.43 +304.06 1.85%
S&P 500 1,987.05 +35.69 1.83%
NASDAQ 4,781.2640 +73.4890 1.56%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs